Collaborative Arrangements (Details Textual 1) (USD $) In Millions, unless otherwise specified	9 Months Ended		12 Months Ended	3 Months Ended		12 Months Ended	6 Months Ended
	Sep. 30, 2012 Takeda Pharmaceutical Company Limited [Member]	Jun. 29, 2012 Takeda Pharmaceutical Company Limited [Member]	Dec. 31, 2008 Takeda Pharmaceutical Company Limited [Member] Japanese market products [Member] Molecule	Sep. 30, 2012 Takeda Pharmaceutical Company Limited [Member] Other revenues [Member]	Jun. 30, 2012 Takeda Pharmaceutical Company Limited [Member] Other revenues [Member]	Dec. 31, 2008 Takeda Pharmaceutical Company Limited [Member] Milestone payments deferred or capitalized [Member]	Jun. 30, 2012 License arrangement for Motesanib with Takeda Pharmaceutical Company Limited [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of molecules developed and commercialized as per collaborations			12
Milestone payment received						$ 300
Amortization period of payments received and deferred under collaborative arrangements, in years						20 years
Deferred revenue as of the date of modification of the original arrangement		230
Milestone payments received under arrangements							3
Incremental cost to be recovered							21
Revenue previously deferred recognized as a result of a material modification to the agreement				24	206
Payments that may be received upon the achievement of various substantive success-based development and regulatory approval milestones	$ 337